查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1463060

迟发性运动障碍治疗药物市场,占有率,规模,趋势,行业分析报告:依药物,产品类型,销售管道,地区,细分市场,预测2024-2032年

Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，到 2032 年，全球治疗迟发性运动障碍的药物市场预计将达到 55.7 亿美元。该报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

各种神经系统和精神疾病的盛行率迅速增加以及对新型疾病特异性治疗的需求不断增加是推动市场成长的关键因素。此外，增加对研究人员和医疗机构的财政支持，以推进医疗保健领域的新颖干预措施和创新，包括迟发性运动障碍治疗，预计将进一步推动市场成长。

例如，2023 年 11 月，Neurocrine Biosciences 推出了 DISCOVER TD，这是一种互动式数位工具，专门用于帮助医疗保健专业人员瞭解和识别迟发性运动障碍。该工具是与临床专家合作开发的。

世界各地需要长期使用抗精神病药物治疗、导致多巴胺水平不正常的精神疾病病例不断增加，增加了对有效治疗的需求。越来越多地采用神经心理学测验来监测和检测认知功能的变化、识别特定模式并提高资讯处理速度，这也推动了市场的成长。例如，根据美国疾病管制与预防中心的报告，美国近五分之一的成年人患有某种形式的精神疾病，近五分之一的年轻人在一生中会经历严重的精神疾病。我有精神疾病。

最近，美国神经病学会指南进行了更新，纳入了两种 FDA 批准的 VMAT2 抑制剂，包括伐苯那秦和氘苯那秦。这些药物是第一个获得 A 级证据支持的药物，主要在美国被批准用于治疗迟发性运动障碍。

迟发性运动障碍治疗药物市场报告亮点

由于人们对迟发性运动障碍及其治疗药物的认识不断提高，伐苯那秦製剂拥有显着的市场占有率

由于医疗专业人员越来越多地采用和高剂量功效，固体剂量部分占据了大部分占有率

由于线上买家的增加以及偏远地区线上药局的出现，线上药局产业预计将以最快的速度成长。

北美由于对该疾病的高度认识、广泛的治疗选择和有利的报销方案而在全球市场占据主导地位。

主要市场参与者有 Reddy Laboratories、SOM Biotech、Luye Pharma Group、Prestwick Pharmaceuticals、Sun Pharmaceuticals Industries、Allergan 等。

目录

第一章简介

第二章执行摘要

第三章研究方法论

第 4 章：迟发性运动障碍治疗的全球市场洞察

  • 迟发性运动障碍治疗药物市场 - 通路快照
  • 迟发性运动障碍药物的市场动态
    • 驱动因素和机遇
      • 研究与开发工作
      • 迟发性运动障碍盛行率上升，公司专注于获得产品批准
    • 限制因素和课题
      • 理解病理生理学的局限性
  • PESTEL 分析
  • 迟发性运动障碍治疗药物市场的通路趋势
  • 价值链分析
  • COVID-19 影响分析

第五章世界药品市场

  • 主要发现
  • 介绍
  • 丁苯那秦
  • 缬苯那秦
  • 其他

第六章依产品类型划分的全球市场

  • 主要发现
  • 介绍
  • 固体剂型
  • 药片
  • 胶囊
  • 液体剂型
  • 注射

第七章依分销通路划分的世界市场

  • 主要发现
  • 介绍
  • 医院药房
  • 药局和药房
  • 网上药店
  • 其他

第八章依地区划分的世界市场

  • 主要发现
  • 介绍
    • 迟发性运动障碍治疗药物市场评估，地区，2019-2032
  • 迟发性运动障碍治疗药物市场－北美
    • 北美：迟发性运动障碍治疗药物市场（依药物），2019-2032
    • 北美：迟发性运动障碍治疗药物市场，依通路划分，2019-2032 年
    • 北美：迟发性运动障碍治疗药物市场，依产品类型，2019-2032
    • 迟发性运动障碍治疗药物市场—美国
    • 迟发性运动障碍药物市场 - 加拿大
  • 迟发性运动障碍药物市场 - 欧洲
    • 欧洲：迟发性运动障碍治疗药物市场（依药物），2019-2032
    • 欧洲：迟发性运动障碍治疗药物市场，依通路划分，2019-2032 年
    • 欧洲：迟发性运动障碍治疗药物市场，依产品类型，2019-2032
    • 迟发性运动障碍治疗市场 - 英国
    • 迟发性运动障碍治疗市场—法国
    • 迟发性运动障碍治疗市场—德国
    • 迟发性运动障碍药物市场—义大利
    • 迟发性运动障碍治疗市场—西班牙
    • 迟发性运动障碍治疗市场 - 荷兰
    • 迟发性运动障碍治疗市场—俄罗斯
  • 迟发性运动障碍治疗药物市场—亚太地区
    • 亚太地区：迟发性运动障碍治疗市场（依药物），2019-2032
    • 亚太地区：迟发性运动障碍治疗药物市场，依通路划分，2019-2032 年
    • 亚太地区：迟发性运动障碍治疗市场（依产品类型），2019-2032 年
    • 迟发性运动障碍治疗药物市场 - 中国
    • 迟发性运动障碍药物市场 - 印度
    • 迟发性运动障碍治疗市场 - 马来西亚
    • 迟发性运动障碍治疗药物市场—日本
    • 迟发性运动障碍治疗市场 - 印度尼西亚
    • 迟发性运动障碍治疗药物市场－韩国
  • 迟发性运动障碍治疗药物市场—中东和非洲
    • 中东和非洲：迟发性运动障碍治疗药物市场（依药物），2019-2032
    • 中东和非洲：迟发性运动障碍治疗药物市场（依分销管道），2019-2032
    • 中东和非洲：迟发性运动障碍治疗药物市场（依产品类型），2019-2032
    • 迟发性运动障碍治疗市场 - 沙乌地阿拉伯
    • 迟发性运动障碍治疗药物市场 - 阿联酋
    • 迟发性运动障碍药物市场 - 以色列
    • 迟发性运动障碍治疗市场 - 南非
  • 迟发性运动障碍治疗药物市场 - 拉丁美洲
    • 拉丁美洲：迟发性运动障碍治疗市场（依药物），2019-2032
    • 拉丁美洲：迟发性运动障碍治疗药物市场，依通路划分，2019-2032 年
    • 拉丁美洲：迟发性运动障碍治疗药物市场（依产品类型），2019-2032 年
    • 迟发性运动障碍药物市场—墨西哥
    • 迟发性运动障碍药物市场 - 巴西
    • 迟发性运动障碍药物市场 - 阿根廷

第9章 竞争格局

  • 扩张和收购分析
    • 扩张
    • 收购
  • 伙伴关係/协作/协议/出版物

第十章公司简介

  • Allergan
  • Contera Pharma
  • Johnson & Johnson Services Inc.
  • Lannett Co. Inc
  • Luye Pharma Group
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences Inc.
  • Prestwick Pharmaceuticals Inc.
  • Reddy Laboratories Ltd.
  • SOM Biotech
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals
Product Code: PM4423

The global tardive dyskinesia therapeutics market size is expected to reach USD 5.57 billion by 2032, according to a new study by Polaris Market Research. The report "Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The drastic increase in the prevalence of various neurological and psychotic disorders and growing need for disease-specific novel treatment, are the leading factors propelling market's growth. Additionally, increase in financial support to the researchers and health institutes for advancing the novel intervention and bring innovations in the healthcare sector including therapeutics for tardive dyskinesia, are further anticipated to drive market's growth.

For instance, in November 2023, Neurocrine Biosciences, introduced DISCOVER TD, which is an interactive digital tool specially designed to help healthcare providers learn and identify about the tardive dyskinesia. Tool is built in collaboration with the clinical experts.

The rising cases of mental illnesses across the globe which requires prolonged treatment with antipsychotic drugs that causes irregular dopamine, fostering the demand for effective therapeutics. Also, the growing adoption of neuropsychological testing for monitoring or detecting changes in cognitive function, identifying specific patterns, and speed of information processing, are also propelling the market's growth. For instance, as per a report by the Centers for Disease Control and Prevention, nearly 1 in 5 US adults live with some form of mental illness, & nearly1 in 5 youth have seriously debilitating mental illness during their life.

Furthermore, the guideline of the American Academy of Neurology was updated recently for incorporating 2 FDA-approved VMAT2 inhibitors including valbenazine & deutetrabenazine, which has been marked as a huge milestone because they had undergone multi-center, randomized, & double-blind clinical trials. They were the first one which is going to be supported by the level A evidence and were mainly approved for the treatment of tardive dyskinesia in the United States.

Tardive Dyskinesia Therapeutics Market Report Highlights

Valbenazine segment accounted for the noteworthy share, on account of rising number of awareness campaigns about such diseases and their therapeutics

Solid dosage form segment held the majority share, driven by its rising adoption by healthcare professionals and higher effectiveness of medication

Online pharmacies segment will grow at highest pace, due to rising number of online buyers and emergence of several online pharmacies for the remotest places

North America dominated the global market, owing to region's greater awareness about disease and wider availability of treatment options, coupled with positive reimbursement scenario

The key market players include Reddy Laboratories, SOM Biotech, Luye Pharma Group, Prestwick Pharmaceuticals, Sun Pharmaceuticals Industries, and Allergan

Polaris Market Research has segmented the tardive dyskinesia therapeutics market report based on drug, product type, distribution channel, and region:

Tardive Dyskinesia Therapeutics, Drug Outlook (Revenue - USD Billion, 2019 - 2032)

  • Deutetrabenazine
  • Valbenazine
  • Others

Tardive Dyskinesia Therapeutics, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Solid Dosage Forms
  • Tablets
  • Capsules
  • Liquid Dosage Form
  • Injection

Tardive Dyskinesia Therapeutics, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Others

Tardive Dyskinesia Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Tardive Dyskinesia Therapeutics Market Insights

  • 4.1. Tardive Dyskinesia Therapeutics Market - Distribution Channel Snapshot
  • 4.2. Tardive Dyskinesia Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Research and Development Initiatives.
      • 4.2.1.2. Increasing prevalence of tardive dyskinesia and focus of companies on gaining product approvals are propelling market growth.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Understanding of Pathophysiology
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Tardive Dyskinesia Therapeutics Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Tardive Dyskinesia Therapeutics Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • 5.3. Deutetrabenazine
    • 5.3.1. Global Tardive Dyskinesia Therapeutics Market, by Deutetrabenazine, by Region, 2019-2032 (USD Billion)
  • 5.4. Valbenazine
    • 5.4.1. Global Tardive Dyskinesia Therapeutics Market, by Valbenazine, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Tardive Dyskinesia Therapeutics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Tardive Dyskinesia Therapeutics Market, by Product Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 6.3. Solid Dosage Form
    • 6.3.1. Global Tardive Dyskinesia Therapeutics Market, by Solid Dosage Form, by Region, 2019-2032 (USD Billion)
  • 6.4. Tablets
    • 6.4.1. Global Tardive Dyskinesia Therapeutics Market, by Tablets, by Region, 2019-2032 (USD Billion)
  • 6.5. Capsules
    • 6.5.1. Global Tardive Dyskinesia Therapeutics Market, by Capsules, by Region, 2019-2032 (USD Billion)
  • 6.6. Liquid Dosage Form
    • 6.6.1. Global Tardive Dyskinesia Therapeutics Market, by Liquid Dosage Form, by Region, 2019-2032 (USD Billion)
  • 6.7. Injection
    • 6.7.1. Global Tardive Dyskinesia Therapeutics Market, by Injection, by Region, 2019-2032 (USD Billion)

7. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Hospitals Pharmacies
    • 7.3.1. Global Tardive Dyskinesia Therapeutics Market, by Hospitals Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Drug Stores & Retail Pharmacies
    • 7.4.1. Global Tardive Dyskinesia Therapeutics Market, by Drug Stores & Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Tardive Dyskinesia Therapeutics Market, by Online Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Tardive Dyskinesia Therapeutics Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Tardive Dyskinesia Therapeutics Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Tardive Dyskinesia Therapeutics Market - North America
    • 8.3.1. North America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.3.2. North America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.3.4. Tardive Dyskinesia Therapeutics Market - U.S.
      • 8.3.4.1. U.S.: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.3.5. Tardive Dyskinesia Therapeutics Market - Canada
      • 8.3.5.1. Canada: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.4. Tardive Dyskinesia Therapeutics Market - Europe
    • 8.4.1. Europe: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.4. Tardive Dyskinesia Therapeutics Market - UK
      • 8.4.4.1. UK: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.5. Tardive Dyskinesia Therapeutics Market - France
      • 8.4.5.1. France: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.6. Tardive Dyskinesia Therapeutics Market - Germany
      • 8.4.6.1. Germany: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.7. Tardive Dyskinesia Therapeutics Market - Italy
      • 8.4.7.1. Italy: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.8. Tardive Dyskinesia Therapeutics Market - Spain
      • 8.4.8.1. Spain: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.9. Tardive Dyskinesia Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.10. Tardive Dyskinesia Therapeutics Market - Russia
      • 8.4.10.1. Russia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.5. Tardive Dyskinesia Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.4. Tardive Dyskinesia Therapeutics Market - China
      • 8.5.4.1. China: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.5. Tardive Dyskinesia Therapeutics Market - India
      • 8.5.5.1. India: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.6. Tardive Dyskinesia Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.7. Tardive Dyskinesia Therapeutics Market - Japan
      • 8.5.7.1. Japan: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.8. Tardive Dyskinesia Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.9. Tardive Dyskinesia Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.6. Tardive Dyskinesia Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.4. Tardive Dyskinesia Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.5. Tardive Dyskinesia Therapeutics Market - UAE
      • 8.6.5.1. UAE: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.6. Tardive Dyskinesia Therapeutics Market - Israel
      • 8.6.6.1. Israel: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.7. Tardive Dyskinesia Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.7. Tardive Dyskinesia Therapeutics Market - Latin America
    • 8.7.1. Latin America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.7.4. Tardive Dyskinesia Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.7.5. Tardive Dyskinesia Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.7.6. Tardive Dyskinesia Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Allergan
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Contera Pharma
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Johnson & Johnson Services Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Lannett Co. Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Luye Pharma Group
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Mitsubishi Tanabe Pharma Corporation
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Neurocrine Biosciences Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Prestwick Pharmaceuticals Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Reddy Laboratories Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. SOM Biotech
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. SteriMax Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Sun Pharmaceutical Industries Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Teva Pharmaceutical Industries Ltd.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Valeant Pharmaceuticals
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development

List of Tables

  • Table 1 Global Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 2 Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 3 Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 6 North America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 7 North America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 9 U.S.: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 12 Canada: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 15 Europe: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 18 UK: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 19 UK: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 21 France: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 22 France: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 24 Germany: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 27 Italy: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 30 Spain: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 36 Russia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 42 China: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 43 China: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 45 India: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 46 India: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 51 Japan: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 57 South Korea: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 66 UAE: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 69 Israel: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 72 South Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 75 Latin America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 78 Mexico: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 81 Brazil: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 84 Argentina: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Tardive Dyskinesia Therapeutics Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Product Type
  • Figure 7. Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug
  • Figure 9. Global Tardive Dyskinesia Therapeutics Market, by Drug, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Tardive Dyskinesia Therapeutics Market